title: Panel discussion 2.
authors.affiliation: Pharmaceutical Companies of Johnson and Johnson, Raritan, New Jersey, USA.
authors.forename: Gordon
authors.initials: G
authors.lastname: Lan
authors.forename: Stacy
authors.initials: S
authors.lastname: Lindborg
authors.forename: James
authors.initials: J
authors.lastname: Neaton
mesh_terms: D015982:Bias; D026661:Clinical Trials Data Monitoring Committees / Q000191:economics; D002986:Clinical Trials as Topic / Q000191:economics / Q000379:methods* / Q000592:standards; D003627:Data Interpretation, Statistical; D057239:Early Termination of Clinical Trials; D023381:Endpoint Determination; D009316:National Institutes of Health (U.S.); D015990:Placebo Effect; D011786:Quality Control; D012107:Research Design; D012109:Research Support as Topic; D014481:United States